Relmada Therapeutics (RLMD) Change in Account Payables (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Change in Account Payables data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 161.5% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 152.66% increase from a year earlier, with the FY2025 full-year figure at -$2.6 million, down 510.15% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.8 million, up from $115842.0 in the prior quarter.
• Over the last five years, Change in Account Payables for RLMD reached as high as $3.2 million in Q2 2022 and fell as low as -$3.5 million in Q3 2022.
• Historically, Change in Account Payables has averaged -$88793.8 across 5 years, with a median of $96901.0 in 2025.
• On a YoY basis, Change in Account Payables climbed as much as 300.38% in 2024 and fell as far as 335.04% in 2024.
• Year by year, Change in Account Payables stood at $1.2 million in 2022, then plunged by 45.33% to $649257.0 in 2023, then surged by 174.93% to $1.8 million in 2024, then slumped by 93.51% to $115842.0 in 2025, then surged by 1421.43% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $1.8 million in Q1 2026, $115842.0 in Q4 2025, and $91191.0 in Q3 2025.